FDA says the Zepbound shortage is over. Here’s what that means for compounding pharmacies, patients who used off-brand versions

CNBC December 24, 2024
Annika Kim Constantino

Key Points

– The Food and Drug Administration announced that branded tirzepatide, the active ingredient in Eli Lilly’s weight loss drug Zepbound, is no longer in short supply.

– That decision will largely prevent compounding pharmacies from making and selling cheaper versions of the drug in the next two to three months.

– It will also leave some patients in limbo, closing a niche market for compounded tirzepatide that patients say helped fill a gap in care for those who say they simply can’t afford to pay out of pocket for Zepbound.

The roughly $1,000 monthly price tag of Eli Lilly‘s weight loss drug Zepbound put the blockbuster treatment out of reach for Willow Baillies, 29, whose insurance does...

Today's Sponsors

Today's Sponsor